跳至主要内容
临床试验/NCT03930914
NCT03930914已完成不适用

Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome

University of Oklahoma2 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2019年11月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
5
试验地点
2
主要终点
Long term effects on M2 muscarinic autoantibody levels

研究概览

简要总结

Postural orthostatic tachycardia (POTS) is characterized by abnormalities in the autonomic nervous system in the body. The autonomic nervous system controls and regulates body functions such as heart rate, breathing, digestion, and more.

The investigator has shown that patients with POTS have higher cardiovascular and adrenergic activating autoantibodies (AAb), which likely changes the normal make-up of POTS. There are autoantibodies that have been suggested by a few reports of their presence in POTS, but their role different aspects of POTS is unknown. The study will look at the body's responses in patients with POTS. The crossover study design is to have half of the patients will start with sham followed by active stimulation and half will start by active followed by sham stimulation. It is anticipated that results will provide a potential therapeutic approach based on the understanding of POTS.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Female or male participants age 18-80
  • Group 1 (20 participants):
  • A physician-based diagnosis of POTS
  • Participants that have a postural pulse rise of >35 for adolescents and >30 for adults with a Blood Pressure (BP) that does not drop >10/5 mmHg will be qualified. These participants may be on salt and fluid loading.
  • Group 2 (10 participants):
  • Previously diagnosed with POTS
  • Patients is on Intravenous immunoglobulin (IVIG) infusion but who have an incomplete symptomatic response

排除标准

  • Age < 18 years
  • Sick sinus syndrome, 2nd or 3rd degree Atrioventricular (AV) block, bifascicular block or prolonged 1st degree AV block (PR>300ms).
  • Currently pregnant women or women planning on becoming pregnant ≤ 6 months
  • History of hypotension due to autonomic dysfunction
  • Have a secondary causes of tachycardia (acute anemia or blood loss, drugs, significant cardiomyopathy, diabetes mellitus)
  • Patients with active implants (such as a cardiac pacemaker, or a cochlear implant).

结局指标

主要结局

Long term effects on M2 muscarinic autoantibody levels

时间窗: 2 and 4 months

The average change in M2 muscarinic autoantibody levels measured from blood specimens obtained after two and four months of daily vagal nerve stimulation.

Long term effects on beta 1-adrenergic autoantibody levels

时间窗: 2 and 4 months

The average change in beta 1-adrenergic autoantibody levels measured from blood specimens obtained after two and four months of daily vagal nerve stimulation.

Long term effects on alpha 1-adrenergic autoantibody levels

时间窗: 2 and 4 months

The average change in alpha 1-adrenergic autoantibody levels measured from blood specimens obtained after two and four months of daily vagal nerve stimulation.

Average change in heart rate variability

时间窗: 2 and 4 months

We will measure the average change in heart rate variability based on 5 minute ECG after two and four months of daily vagal nerve stimulation

Average change in orthostatic heart rate

时间窗: 2 and 4 months

We will measure the average change in heart rate between supine and standing using continuous ECG after two and four months of daily vagal nerve stimulation

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验